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Background: There is little information concerning infective endocarditis (IE) in patients with 
bicuspid aortic valve (BAV) / mitral valve prolapse (MVP), and IE antibiotic prophylaxis (IEAP) 
is currently not recommended for these conditions. 
Objectives: To describe the clinical and microbiological features of IE in patients with BAV and 
MVP and compare them with those of IE patients with and without IEAP indication, to 
determine the potential benefit of IEAP in these conditions.   
Methods: This analysis involved 3,208 consecutive IE patients prospectively included in the 
GAMES registry at 31 Spanish hospitals. Patients were classified as high-risk IE with IEAP 
indication (high-risk group; n=1,226), low and moderate-risk IE without IEAP indication 
(low/moderate-risk group; n=1,839), and IE with BAV (n=54) or MVP (n=89). 
Results: BAV and MVP patients had a higher incidence of viridans group Streptococci (VGS) 
IE than high-risk group and low/moderate-risk group patients (35.2% and 39.3% vs 12.1% and 
15%, respectively, all p<0.01). A similar pattern was seen for IE from suspected odontological 
origin (14.8% and 18% vs 5.8% and 6%, all p<0.01). BAV and MVP patients had more 
intracardiac complications than low/moderate-risk group (50% and 47.2% vs 30.6%, both 
p<0.01) and similar to high-risk group patients.  
Conclusions: IE in patients with BAV and MVP have higher rates of VGS IE and IE from 
suspected odontological origin than in other IE patients, with a clinical profile similar to that of 
high-risk IE patients. Our findings suggest that BAV and MVP should be classified as high-risk 
IE conditions and the case for IEAP should be reconsidered. 
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Condensed abstract: We sought to describe the clinical and microbiological features of IE in 
BAV and MVP and compare them with those of IE patients with and without IEAP indication. 
Data from 3,208 consecutive IE patients were analyzed. When comparing BAV (n=54) and MVP 
(n=89) with IE patients with (n=1,226) and without (n=1,839) IEAP indication, BAV and MVP 
exhibited higher incidence of viridans group streptococci IE (35.2% and 39.3% vs 12.1% and 
15%, all p<0.01) and higher suspected odontological origin (14.8% and 18% vs 5.8% and 6%, all 




BAV=bicuspid aortic valve 
MVP=mitral valve prolapse 
IEAP=infective endocarditis antibiotic prophylaxis  
AHA=American Heart Association 
ESC=European Society of Cardiology 
CHD=congenital heart disease 
HF=Heart Failure 
VGS=viridans group streptococci 
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Introduction  
Infective endocarditis (IE) is a rare disease with a high in-hospital mortality of 25% to 
30% despite early diagnosis and advances in surgical and antibiotic treatments (1). Thus, it is 
important that efforts are directed towards preventive strategies that reduce the number of 
patients with IE. Antibiotic prophylaxis for IE (IEAP) is one of the strategies proposed to prevent 
IE. 
IEAP was initially proposed in 1955 (2) and it has evolved over the past 50 years (3-9) 
founded on expert opinion and small case-control studies (10-14). Based on the risk of IE 
throughout life and the risk of complications from IE, predisposing cardiac conditions are 
classified as low-, intermediate- and high-risk, and IEAP was initially recommended for both 
intermediate and high-risk conditions (8). However, due to the lack of solid data the American 
Heart Association (AHA) in 2007 (9) and the European Society of Cardiology (ESC) in 2009 
(15), restricted the recommendation for IEAP to only high-risk patients.  
Bicuspid aortic valve (BAV) and mitral valve prolapse (MVP) are frequent cardiac 
abnormalities that show a higher incidence of IE than the general population (16-19). BAV and 
MVP are currently considered intermediate-risk cardiac conditions, and were among the 
conditions for which IEAP was restricted. 
Several studies have shown a nationwide increase in the incidence of IE in individuals at 
high- and moderate-risk in the United Kingdom (20) and a rise in streptococcal IE in those at 
moderate-risk in the United States (21), Canada (22), Germany (23) and the Netherlands (24) 
after the IEAP restriction. Accordingly, there remains controversy regarding the benefits of IEAP 
and which patients should receive it. Specifically, there is very little information on IE in 
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intermediate-risk cardiac conditions like BAV and MVP, and data about the potential usefulness 
of IEAP in individuals with these diseases are limited. 
The aim of this study was twofold: first, to describe the clinical and microbiological 
features of BAV and MVP patients with IE; and second, to compare these features with those of 
patients with and without IEAP indication, in order to gain insight about the potential usefulness 
of IEAP to prevent IE in these situations.  
Methods 
From January 2008 to September 2016, 3,524 consecutive patients with confirmed or 
possible IE according to the modified Duke criteria were prospectively included in the Spanish 
Collaboration on Endocarditis–Grupo de Apoyo al Manejo de la Endocarditis infecciosa en 
España (GAMES) registry, at 31 Spanish hospitals (25-30). Of the 31 hospitals participating in 
the GAMES registry, 24 are tertiary centers with cardiac surgery onsite and 7 are community 
hospitals. Regional and local ethics committees approved the study and patients gave their 
informed consent. Multidisciplinary IE teams completed a standardized case report document 
with each IE episode, which included clinical, microbiological and echocardiographic sections. 
Patients were classified according to underlying cardiac conditions and IEAP indication. IEAP 
indications were based on current AHA/ESC recommendations (9,15). Hence, patients with 
previous IE, prosthetic valves, unrepaired cyanotic congenital heart disease (CHD), repaired 
CHD with residual defects, and patients with CHD and less than 6 months since surgery, were 
considered high-risk patients with an established indication of IEAP (high-risk group). IE was 
considered prosthetic when it occurred in biological or mechanical prostheses or in reconstructed 
native heart valves. 
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The remaining low- and moderate-risk patients without an established indication of IEAP 
constituted the low/moderate-risk group, after excluding those individuals with BAV and MVP 
(Figure 1). Patients with isolated device-related IE (n=316) were excluded from the analysis. 
Major IE adverse events considered were heart failure (HF), peripheral embolism, 
embolic stroke, persistent bacteremia (>7 days) and intracardiac complications. Indication for 
cardiac surgery was decided by treating IE teams based on ESC recommendations (15,31).  
Microbiological data and the suspected portal of entry were recorded prospectively by the 
participating centers in the GAMES form. Regarding the determination of the causal 
microorganism, the centers recorded the isolated microorganism in blood cultures or in the 
surgically removed valve during admission. To consider a microorganism as causal at least 2 
positive cultures were required. The flora of the oral microbiome comprised all microorganisms 
whose main reservoir is the oropharynx (32,33).  
In relation to the suspected portal of entry, this was established prospectively by the local 
teams during admission, based on patient history and physical examination. Teams determined 
the probable portal of entry at their discretion if factors like poor oral hygiene, previous 
odontological procedures, previous phlebitis or concomitant line infection were present. 
Clinical, echocardiographic, microbiological features and adverse events of BAV and 
MVP patients were compared with those of patients from high-risk group and low/moderate-risk 
group. 
Statistical analysis 
Variables with normal distribution were expressed as mean and standard deviation (SD), 
while non-normal distribution variables were described with median and interquartile range 
(IQR). Univariate analysis of data comparisons between two groups was performed using the 
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unpaired Student t-test for continuous variables with normal distribution, or by the Mann-
Whitney U test in the case of variables with non-normal distribution. Chi square or Fisher exact 
tests were used for the categorical variables. A value of p<0.05 was considered statistically 
significant. All hypothesis tests were bilateral. All statistical analysis was performed with SPSS 
Statistics (version 16.0). 
 
Results 
A total of 3,208 patients with definite (n=2593, 80.8%) or possible (n=615, 19.2%) IE 
were included in the study. Of these, 54 were patients with BAV (1.6%), 89 were patients with 
MVP (2.7%), 1,226 (38.2%) were high-risk patients with IEAP indication (Group 1), and 1,839 
(57.3%) were low/moderate-risk patients without IEAP indication (Group 2). 
Infective endocarditis in patients with bicuspid aortic valve  
The BAV group comprised 54 patients; the majority were male (43, 79.6%), with a 
median age of 43 years (IQR: 36–55) and low comorbidity. At the time of IE diagnosis, 33 
patients (61%) had moderate/severe aortic valve dysfunction (Table 1). Concomitant 
involvement of the other valve was observed in 10 (18.5%) patients. The median time of 
hospitalization was 33 days (IQR: 18–50).  
Most cases of IE (46, 85.1%) had been acquired in the community. The most common 
organisms causing IE were microorganisms present in the oral cavity (42.6%), mainly viridans 
group streptococci (VGS) (35.2%), and the most frequently identified entry portal was the oral 
cavity (14.8%) (Table 2). 
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Intracardiac complications and HF were common (50% and 40.7%, respectively). Cardiac 
surgery was indicated in 75.9% and performed in 68% of patients. The in-hospital mortality was 
5.6% (Table 3). 
Infective endocarditis in patients with mitral valve prolapse  
The MVP group comprised 89 patients; the majority were male (60, 67.4%), with a 
median age of 63 years (IQR: 45–71). At the time of IE diagnosis, moderate/severe mitral 
regurgitation was present in 50 patients (56%) (Table 1). The median time of hospitalization was 
32 days (IQR: 19–45).  
Again, most cases of IE were due to bacteria of the oral microbiome (46.1%), mainly 
VGS (39.3%), and the oral cavity was the most frequent suspected entry portal (18%) (Table 2). 
Intracardiac complications and HF were also very frequent and were present in 47.2% 
and 34.8% of patients, respectively. Cardiac surgery was indicated in 56 (62.9%) and performed 
in 35 (39.3%) patients. The majority of individuals who underwent surgery received a 
mechanical prosthesis (60%), and 59 patients (66.3%) had severe mitral regurgitation at 
discharge. The in-hospital mortality of individuals who underwent cardiac surgery was 3% and 
10% in the entire MVP group (Table 3). 
Infective endocarditis in BAV and MVP versus infective endocarditis in patients with and without 
IEAP indication 
BAV and MVP patients were younger and had fewer comorbidities than patients from 
Groups 1 and 2 (Table 1).  
There was a higher incidence of VGS IE in BAV and MVP patients than in high-risk 
group (35.2% and 39.3% vs 14.6%, both p<0.01) and low/moderate-risk group (35.2% and 
39.3% vs 15%, both p<0.01) patients. Furthermore, BAV and MVP patients showed higher rates 
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of IE from suspected odontological origin than did high-risk group (14.8% and 18% vs 5.8%, 
both p<0.01) and low/moderate-risk group (14.8% and 18% vs 6%, both p<0.01) patients. While 
VGS were the most frequent causal microorganisms in BAV and MVP groups, staphylococci 
were the most frequent organisms in high-risk and low/moderate-risk groups (Table 2). 
Furthermore, these findings were mantained when BAV and MVP groups were compared with 
isolated native aortic valve IE and isolated mitral valve IE, respectively (Online Appendix). 
As nosocomial IE was more frequent in high-risk and low/moderate-risk groups than in 
BAV and MVP (Table 2), a subgroup analysis was performed including only those patients with 
community-acquired IE. Again, BAV and MVP groups showed a higher proportion of VGS IE 
and suspected oral cavity entry portal than did high-risk and low/moderate-risk groups (Central 
Illustration and Online Appendix). Again, BAV and MVP groups showed a higher proportion 
of VGS IE when they were compared with isolated native aortic valve and isolated mitral valve 
community-adquired IE, respectively (Online Appendix). 
As shown in Table 3, BAV and MVP patients had similar intracardiac complications to 
those of the high-risk group (50% and 47.2% vs 44.8%, p<0.53 and p<0.74, respectively), which 
were more frequent than those in patients from the low/moderate-risk group (50% and 47.2% vs 
30.6%, both p<0.01) (Central illustration). BAV patients had a significantly higher need for 
surgical treatment than did patients in the low/moderate-risk group (75.9% indicated and 68% 
performed vs 62.2% indicated and 40.6% performed, p<0.05 and p<0.01, respectively). In 
comparison with the high-risk group, a significantly higher number of BAV patients underwent 
surgery (68% vs 40%, p<0.01). No differences were found regarding surgery indicated and 
performed in the MVP group versus the high-risk and low/moderate-risk groups. 
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In-hospital mortality of BAV and MVP groups (5.6% and 10.1%, respectively) was 
significantly lower than that of the high-risk and low/moderate-risk groups, which showed 
similar mortality rates (29% and 28.3%, respectively, both p<0.01). To further investigate these 
differences in in-hospital mortality, we analyzed several factors known to be associated with an 
adverse prognosis in IE. Results of this analysis showed that patients from high-risk and 
low/moderate-risk groups were older, had higher comorbidity rates and higher surgical risk, and 
contracted nosocomial IE and staphylococcal IE more frequently than did patients with BAV and 
MVP (Table 4). When a propensity score analysis was performed between MVP and BAV 
individuals and high- and low/intermediate-risk subjects matched according to age, Charlson 
index, nosocomial IE, staphylococcal IE and LogEuroscore, in-hospital mortality rates between 
the BAV and MVP groups and the high-risk and low/moderate-risk groups were not statistically 
different (Online Appendix). 
Discussion  
This study presents the largest series yet described of IE in patients with BAV and MVP. 
It shows that patients with these cardiac conditions who contract IE are young and predominantly 
male individuals with few comorbidities. Despite this, the analysis of the clinical characteristics 
in BAV and MVP patients with IE revealed an aggressive clinical course with a similar 
proportion of IE complications to that of IE patients with high-risk cardiac conditions, and more 
intracardiac complications than in patients of the low- and intermediate-risk groups. Moreover, 
this study shows that the microbiological and epidemiological profile of IE in BAV and MVP 
patients differs substantially from that found in patients with other low- and intermediate-risk 
cardiac conditions, with a particularly high rate of VGS IE and also a more frequent rate of IE 
from suspected odontologic origin. Overall, our findings open the debate to consider IEAP 
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before dental procedures not only in high-risk cardiac conditions, but also in patients with BAV 
and MVP. 
BAV is the most common form of congenital heart disease (prevalence of 0.5–2%). 
Patients with BAV have an IE incidence of 236 cases per 100,000 individuals/year (16,17), 
which represents a ~30-fold higher risk of IE than in the general population (5–7 cases per 
100,000 individuals/year).(1) MVP is also a frequent cardiac condition (prevalence of 2–3%) and 
it is thought to be the most frequent predisposing cardiac condition for IE in developed countries. 
Accordingly, MVP patients have been reported to present an IE incidence of 87 per 100,000 
habitants/year, which is higher than that for flail leaflet or mitral regurgitation (18,19). In spite of 
the abovementioned facts, BAV and MVP are considered intermediate-risk cardiac conditions 
and IEAP is presently not recommended. 
Current AHA and ESC recommendations for IE prevention restrict IEAP to patients with 
high-risk cardiac conditions based on the hypothesis that the potential risks associated with IEAP 
(antibiotic side-effects and increase in resistant microorganisms) could exceed its benefits in 
those who are not high-risk. 
The benefits were questioned because of the lack of randomized-controlled data of IEAP 
efficacy to prevent IE, and because IE seems to be most frequently caused by bacteremia 
provoked by routine daily activities; therefore, even if IEAP is effective, it would prevent only a 
small number of IE cases (9). 
Nevertheless, the reality is that previous studies on IE in intermediate-risk cardiac 
conditions like BAV and MVP are scarce and insufficient to evaluate IE characteristics and 
prognosis in these patients; however, a very recent study has shown that several intermediate-risk 
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conditions present a similar risk of developing or dying from IE than some of those conditions 
currently considered high-risk (34). 
Furthermore, whereas several nationwide studies performed in North America and 
Europe have shown an epidemiological increase in IE and streptococcal IE following IEAP 
restrictions (20-24), other studies have not found this to be the case (35-37). Moreover, a recent 
nationwide population-based cohort study has shown a protective effect of IEAP in individuals 
with prosthetic heart valves, and the only available meta-analysis on IEAP in dental procedures 
has also suggested a protective effect, despite the limitation of the poor quality of the primary 
studies (38,39). In addition, if the increase in the population trends of IE is assumed to be due to 
IEAP restriction, IEAP would be cost-effective (40). 
It is unlikely that a prospective randomized placebo-controlled trial will ever be 
conducted to evaluate the efficacy of IEAP in dental procedures in intermediate- or even in high-
risk cardiac conditions. This is due to the generally low incidence of IE, the wide variety of 
predisposing heart conditions, and the different types of dental procedures, which make it very 
difficult to carry out such types of studies. Because of this, registry-based investigations 
addressing clinical, microbiological and echocardiographic characteristics of IE in patients with 
intermediate-risk cardiac conditions, and on which patients might benefit more from IEAP, are 
extremely necessary. 
In the present study, we analyzed clinical and microbiological findings in the largest 
series of BAV and MVP with IE reported to date, and compared these with those of IE in 
patients with high-risk cardiac conditions where IEAP is advocated, and of IE patients with low 
and other intermediate risk cardiac conditions for whom IEAP is currently not recommended. 
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Until now, IE data in BAV were almost restricted to BAV series where a maximum of 4 
to 13 individuals had this complication (16,17). In those series, around 70% of patients with 
BAV and IE underwent cardiac surgery, which is similar to the percentage of individuals 
operated upon in our registry (68%). Of note, the number of BAV patients with IE requiring 
cardiac surgery (75.9% indicated and 68% performed) was much higher than in the 
low/intermediate group (indicated in 62.2% and performed in 40.6%, p<0.05 and p<0.01, 
respectively) and also in the high-risk group (indicated in 64.3% and performed in 40.9%, 
p<0.11 and p<0.01, respectively). The number of individuals operated upon is also higher than 
what has been reported in both native and prosthetic IE series (surgical treatment around 50%) 
(41,42). The high surgery rate found in these patients illustrates the importance of preventing IE 
to avoid risks associated with cardiac surgery, but also long-term complications derived from 
prosthetic valves and anticoagulation therapy. 
The clinical course of IE in MVP patients has never been described in detail in the 
literature due to the small number of cases reported. In the largest contemporary series of 
individuals with MVP, only 8 subjects developed IE, 2 of whom required emergent surgery (19). 
However, it is important to mention the high risk of IE reported in MVP patients with 
moderate/severe mitral regurgitation and those with flail leaflet: 289.5 cases/100.000 person-
years and 715.5 cases/100.000 person-years, respectively (19). 
In our series, we found that the need for cardiac surgery in the MVP group was similar to 
that found in low/intermediate and high-risk groups. However, a non-negligible percentage of 
MVP patients with IE (66.3%) had severe mitral regurgitation at discharge, which carries 
substantial risk of developing HF and requiring cardiac surgery during follow-up. 
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We also found a relatively low in-hospital mortality rate both in BAV and MVP patients. 
Nevertheless, an in-hospital mortality of 5 to 10% should be still considered very high given the 
young age and the few comorbidities of patients included in these groups. 
One of the most interesting findings of our work was the profound differences between 
groups regarding the IE microbiological profile and the rate of IE from suspected odontological 
origin. While staphylococci were the predominant IE-causing agents in patients with IEAP 
indication and also in the non-indicated IEAP group, VGS were the most frequent in patients 
with BAV and MVP (35.2% and 39.3% of cases, respectively). Furthermore, the odontological 
portal of entry was the most common origin of IE identified in BAV and MVP patients (14.8% 
and 18%, respectively), and it was significantly higher than that in the high-risk group (5.8%) 
and low/intermediate-risk group (6%). To determine whether IEAP is effective in preventing IE 
is beyond the scope of our study, but it is interesting to hypothesize that the microbiological 
spectrum found in patients with IEAP indication could have been influenced by IEAP, while the 
microbiological spectrum in IE patients with BAV and MVP reflects the absence of IEAP and an 
increased risk of IE compared with other low/intermediate-risk conditions. 
Regarding IE adverse events, both BAV and MVP groups had more intracardiac 
complications than the low/intermediate-risk group (50% and 47.2% vs 30.6%, respectively, 
both p<0.01) and similar to the high-risk group (50% and 47.2% vs 44.8%, p<0.53 and p<0.74). 
Of note, the incidence of intracardiac complications found in BAV and MVP patients are higher 
than that previously reported in native valve IE and is similar to that described in prosthetic valve 
IE (43). 
In any case, the microbiological spectrum, the increased odontological origin and the high 
rate of intracardiac complications and surgery (comparable to the high-risk group) (central 
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illustration) poses the question of whether IEAP should be reconsidered for patients with BAV 
and MVP. 
Limitations  
This study has some limitations. The information regarding IEAP prior to odontological 
procedures was not included in the GAMES registry database. However, all the study 
participants were included after the publication of the 2007 IE guidelines that restricted IEAP to 
high-risk patients (11). The total number of BAV and MVP patients among the population under 
care at the 31 participating centers is unknown, so we cannot provide incidence or prevalence 
data. However, ours is the largest series yet described of IE in patients with BAV and MVP. 
Conclusions 
IE patients with BAV and MVP present a distinct clinical and microbiological profile that 
includes young age, male preponderance and low comorbidity. They also present higher rates of 
VSG IE and increased IE from suspected dental origin than other IE patients. IE patients with 
BAV and MVP present a clinical course similar to that of high-risk patients, with more 
intracardiac complications than the low/intermediate-risk group and a higher need for surgery in 
the case of IE BAV patients. Based on these indirect data, we suggest that BAV and MVP should 
be considered high-risk IE cardiac conditions, and that IEAP indication should be reconsidered 
for this group of patients. 
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Perspectives 
Competency in medical knowledge: Individuals with BAV and PVM have a higher risk of 
developing IE than the general population. IE in BAV and PVM is characterized by an 
aggressive clinical course, comparable to that of high-risk patients in terms of adverse events, 
and with a higher surgical need in BAV patients.  
Translational outlook: Further studies are needed to assess IEAP efficacy and to determine 
which patients might benefit from IEAP.  
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Figure Legends 
Central illustration. Main distinctive microbiological and clinical findings in BAV and 
MVP patients with IE compared with high-risk and low/intermediate-risk IE cardiac 
conditions. IE patients with BAV and MVP present higher rates of viridans group streptococci 
IE and increased IE from suspected dental origin. They present more intracardiac complications 
than the low/intermediate-risk group and a higher need of surgery in IE BAV patients.  IE: 
infective endocarditis; VGS: viridans group streptococci 
Figure 1. Study overview. Data from 3,524 consecutive IE patients prospectively included in 
the GAMES registry. IE: infective endocarditis; IEAP: infective endocarditis antibiotic 
prophylaxis; BAV: bicuspid aortic valve; MVP: mitral valve prolapse. 
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Table 1. Baseline characteristics in bicuspid aortic valve and mitral valve prolapse patients in comparison with high-risk and low/moderate-risk 
groups 
Variable 
BAV MVP High-risk group 
Low/moderate-
risk group 




BAV vs  
Low/moderate-
risk group , 





(n = 54) (n = 89) (n = 1226) (n =1839) p-value p-value p-value 
Male, n (%) 43 (79.6) 60 (67.4) 730 (59.5) 1115 (60.6) <0.01 <0.01 0.17 0.24 
Age  (years), median (IQR) 43 (36–55) 63 (45–71) 69 (59–77) 69 (56–77) <0.01 <0.01 <0.01 <0.01 
Diabetes mellitus 2, n (%) 7 (13) 10 (11.2) 314 (25.6) 538 (29.3) <0.03 <0.03 <0.01 <0.01 
Arterial hypertension, n (%) 12 (22.2) 33 (37.1) 714 (58.4) 998 (54.4) <0.01 <0.01 <0.01 <0.01 
Dyslipidemia, n (%) 9 (16.7) 14 (15.7) 484 (39.6) 577 (31.5) <0.01 <0.04 <0.01 <0.01 
Ischemic heart disease, n (%) 5 (9.4) 13 (14.6) 398 (32.5) 363 (19.8) <0.01 0.16 <0.01 0.46 
Atrial fibrillation, n (%) 2 (3.7) 12 (13.5) 485 (39.7) 333 (18.1) <0.01 <0.02 <0.01 0.36 
CKD mod/sev, n (%) 1 (1.9) 5 (5.6) 177 (14.4) 308 (16.8) <0.03 <0.01 0.06 <0.01 
Hepatic disease, n (%) 2 (3.7) 7 (7.8) 95 (7.7) 240 (13) 0.4 0.06 0.86 0.2 
Neoplasia, n (%) 1 (1.9) 13 (14.8) 170 (13.9) 337 (18.4) <0.01 <0.01 0.81 0.65 
Immunossuppresive therapy, n (%) - 3 (3.4) 51 (4.2) 148 (8.1) 0.26 0.07 0.72 0.19 
HIV, n (%) 3 (5.6) 3 (3.4) 12 (1) 44 (2.4) <0.01 0.33 0.12 0.72 
Charlson index (adjusted by age), median 
(IQR) 
1 (0–2) 3 (1–4) 5 (3–6) 5 (3–7) <0.01 <0.01 <0.01 <0.01 
Valve dysfunction, n (%) 
Aortic regurgitation 
-Moderate, 14 (26) 
-Severe, 19 (35.1) 
 
Aortic stenosis 
-Moderate, 4 (7.4) 
-Severe, 2 (3.7) 
Mitral regurgitation 
-Mild, 8  (9) 
-Moderate, 21 (23.6) 
-Severe, 29 (32.5) 
NA NA NA NA NA NA 
Cardiac risk conditions, n (%) NA Cardiac device, 1 (1.1) 
Prosthesis, 1055 
(86.1%) 






Rheumatic, 99 (5.3) 
 
Cardiac device, 123 
(6.7) 




BAV:bicuspid aortic valve; MVP: mitral valve prolapse; CKD: chronic kidney disease; HIV: human immunodeficiency virus; HCM: hypertrophic cardiomyopathy; NA=not applicable; IQR: 



















Table 2. Microbiological profile of the study groups 
 
 BAV 
(n = 54) 
MVP 
(n = 89) 
High-risk group 
(n = 226) 
Low/moderate-
risk group 



















Nosocomial IE, n (%) 5 (9.2) 7 (7.8) 441 (35.9) 456 (24.7) <0.01 <0.01 <0.01 <0.01 
IE portal of entry, n (%) 
 Odontological 
 Vascular  





























































Flora of the oral microbiome  
       VGS, n (%) 
       Granullicatella sp. 
       Abiotrophia sp. 
       Gemella sp. 
       HACEK  
Non-oral streptococci 
     Nasopharynx streptococci 
     S. gallolyticus 
     S. agalactiae 
Staphylococci 
      S. aureus, n (%) 
             MARSA 
      CNS, n (%) 
Enterococcus faecalis, n (%) 
Non-HACEK gram-negative bacilli, n (%) 
Negative blood cultures, n (%) 


























































































































































BAV: bicuspid aortic valve; MVP: mitral valve prolapse; IE: infective endocarditis; VGS: viridans group streptococci;  HACEK: hemophilus parainfluenzae, H.aphrophilus, H.paraphrophilus, 






























BAV: bicuspid aortic valve; MVP: mitral valve prolapse; CNS: central nervous system; IQR: interquartile range; * number of patients with 1 cardiac complication ; 
Ø number of patients with 1 peripheral embolism 
Variables BAV 
(n = 54) 
MVP 
(n = 89) 
High-risk group 
(n = 1226) 
Low/moderate
-risk group 
(n = 1839) 


















Admission (days), median (IQR) 33 (18–50) 32 (19–45) 38 (20–54) 36 (22–51) 0.4 0.37 0.23 0.18 
Heart failure, n (%) 22 (40.7) 31 (34.8) 473 (38.5) 826 (45) 0.8 0.64 0.26 0.06 




0.53 <0.01 0.74 
 
<0.01 






























- - - - 
Neurological events, n (%) 
 CNS embolism, n (%) 
 CNS embolism with haemorrhagic 
transformation, n (%) 









































Peripheral embolism Ø, n (%) 9 (18.4) 19 (21.3) 204 (16.7) 443 (24.1) 0.6 0.3 0.51 0.83 
Persistent bacteriemia, n (%) 3 (5.6) 2 (2.2) 129 (10.6) 231 (12.6) 0.25 0.16 <0.04 <0.01 
Cardiac surgery indication, n (%) 41 (75.9) 56 (62.9) 789 (64.3) 1145 (62.2) 0.11 <0.05 0.87 0.98 
 LogEuroscore, median (IQR) 

















Cardiac surgery performed, n (%) 37 (68) 35 (39.3) 502 (40.9) 748 (40.6) <0.01 <0.01 0.97 0.77 
Surgical procedures, n (%) 
 Mechanical prosthesis implant 
 Biological prosthesis implant 
 Valve repair 





















- - - - 





Table 4. In-hospital mortality according to poor prognosis factors  
 
 




(n = 54) 
MVP 
(n = 89) 
High-risk 
group 
(n = 1226) 
Low/moderate-
risk group 





BAV vs  
Low/moderate-
risk,   
p-value 




MVP vs  
Low/moderate-
risk ,  
p-value 
Age  (years), median (IQR) 43 (36–55) 63 (45–71) 69 (59–77) 69 (56–77) <0.01 <0.01 <0.01 <0.01 
Charlson index (adjusted by age), median (IQR) 1 (0–2) 3 (1-4) 5 (3–6) 5(3–7) <0.01 <0.01 <0.01 <0.01 
Nosocomial IE, n (%) 5 (9.2) 7 (7.8) 441 (35.9) 456 (24.7) <0.01 <0.01 <0.01 <0.01 
Staphylococcal IE, n (%) 8 (14.8) 16 (18) 450 (37) 765 (41) <0.01 <0.01 <0.01 <0.01 
LogEuroscore, median (IQR) 4 (3–18) 6 (4–21) 34 (16–60) 15 (6–36) <0.01 <0.01 <0.01 <0.01 
